NEW YORK, March 27, 2012
NEW YORK, March 27, 2012 /PRNewswire/ -- TheraBiogen, Inc. (OTC BB: TRAB), a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches, announced today that the Company has contacted India's Minister of Health to offer to donate a quantity of Thera Max Cold and Flu product to aid in the current outbreak of Swine (H1N1) flu in four of India's states.
Kelly Hickel, CEO of TheraBiogen, commented, "We hope to be of help to the people of India in this time of need by providing our TheraMax product, which has been proven to be effective in inhibiting the adsorption of the flu virus."
According to a published study conducted last year by the Institute for Antiviral Research at Utah State University, "TheraMax delayed symptoms during animal infections" and "TheraMax….and Oseltamivir (Tamiflu) each prevented death and …. Reduced lung haemorrhage scores." Additionally, the study concluded that, "The results…support the mode of action of Thera Max as an inhibitor of virus adsorption into cells."
Thera Max® Cold and Flu is an all-natural, non-zinc, non-addictive, over-the-counter cold flu relief agent. Over 50 million Americans contract the flu each year and consumer demand for a homeopathic, non-zinc remedy is estimated to be a 2.5 billion dollar market.
Thera Max® is available for purchase in over twelve thousand locations including Rite-Aid, Food Lion, Hannaford Supermarkets, Discount Drug Marts, Big Y Supermarkets and other major retailers. For more information on Thera Max® visit our website at www.theramaxrelief.com, our Facebook page at facebook.com/theramaxnasalspray or follow us on Twitter at http://twitter.com/TheraMaxRelief.
About TheraBiogen, Inc.TheraBiogen is a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches. The products are made from natural, homeopathic ingredients and contain no zinc, which has been identified as potentially causing nasal problems in other similar products on the market. For further information please visit www.theramaxrelief.com.
Safe Harbor StatementThis press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. TheraBiogen, Inc. assumes no obligation to update the statements contained in this release except as required by applicable securities laws disclosure rules.
Public Relations Contact:
Boutcher & Boutcher
Kelly T. Hickel, CEO
Megale Public Relations
SOURCE TheraBiogen, Inc.PR Newswire
Last updated on: 27/03/2012
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.